Understanding How FDA Regulates Stem Cell and Exosome Products
A plain-language, source-cited public education resource on the federal law, FDA pathways, and manufacturing standards that govern mesenchymal stem cell (MSC) and MSC-derived exosome products in the United States — plus a summary of the current peer-reviewed research for three specific conditions.
1. 351(a) vs. 361 Pathways
The single most important regulatory distinction in this field — and the one most often blurred in marketing.
Read the explainer →2. Why 361 Products Are Restricted
Structural, homologous, non-systemic use only — and why that is not the same thing as an approved drug.
Read the explainer →3. The Federal Right to Try Act
What the 2018 federal law actually covers, and the narrow conditions that must be met.
Read the explainer →4. State Law (6-State Survey)
Why state statutes cannot legalize an FDA-unapproved biologic, and what a representative sample of states have tried anyway. Partial survey, not all 50 states.
Read the explainer →5. ISO 5 Cleanrooms & cGMP
What cleanroom classification and manufacturing-quality regulation actually require.
Read the explainer →6. RUO Labeling & Release Testing
Why "Research Use Only" is not a legal safe harbor, and what release testing is actually expected.
Read the explainer →7. TBI Research Summary
20 recent PubMed-indexed studies on MSC/exosome approaches to traumatic and acquired brain injury.
Read the summary →8. COPD Research Summary
20 recent PubMed-indexed studies on MSC/exosome approaches to COPD.
Read the summary →9. Knee OA Research Summary
20 recent PubMed-indexed studies on MSC/exosome approaches to knee osteoarthritis.
Read the summary →10. Full Legal Disclaimer
Complete terms of use, scope limitations, and no-guarantee language for this entire site.
Read the disclaimer →Why this site exists
Regenerative medicine — including mesenchymal stem cell (MSC) therapy and MSC-derived exosome products — is one of the fastest-growing and most misunderstood areas of FDA regulation. Marketing claims from clinics and product sellers frequently blur three separate legal questions: (1) whether a product is even lawful to sell or administer under federal law, (2) whether a state statute changes that answer (it generally does not), and (3) whether "Research Use Only," "FDA-registered," or "Right to Try" language means what a reasonable consumer would assume it means (it usually does not).
This site was built as a plain-language, source-cited public education reference on those questions. It was drafted by a regulatory compliance professional with an FDA/CBER background — not a licensed physician and not a licensed attorney — and every regulatory or scientific claim is cited to a primary source (the U.S. Code, the Code of Federal Regulations, FDA guidance, FDA enforcement letters, or peer-reviewed literature indexed on PubMed) or is explicitly flagged where a primary source could not be confirmed.
What this site is not
This site does not sell, market, or recommend any specific product, clinic, treatment, or provider. It does not diagnose or recommend treatment for traumatic brain injury, COPD, knee osteoarthritis, or any other condition. Where it summarizes peer-reviewed research on a condition, that summary is provided to describe the current state of the published scientific literature — it is not a claim that any product is safe or effective for treating that condition, and it is not a substitute for a conversation with a licensed physician.
Sources cited in this section
- U.S. Food & Drug Administration, Center for Biologics Evaluation and Research (CBER) — public guidance and enforcement materials cited throughout this site, primarily at fda.gov.
- National Library of Medicine, PubMed — peer-reviewed literature searches cited on the condition-specific pages.